Stroke is a leading cause of death and disability worldwide. In Australia, someone suffers a stroke every 11 minutes. There is a large unmet need for a drug that can reduce brain injury following stroke, whilst waiting for blood flow to be restored. Argenica Therapeutics is an Australian company that has generated extensive preclinical data demonstrating the potent multi-modal neuroprotective properties of its lead drug, ARG-007, in cell culture and animal models of stroke.
A Phase I clinical trial confirmed ARG-007 is safe and well tolerated in healthy volunteers. Recruitment has recently been completed for a Phase 2 clinical trial in acute ischaemic stroke (AIS) patients which is aiming to determine the safety and preliminary efficacy of ARG-007 in AIS.
The TTRA Project funding will support the Australian activities in a global Phase 2b/3 pivotal trial, led from Australia, aiming to demonstrate the efficacy of ARG-007 in reducing global disability following AIS. This research will provide essential evidence to support the commercial translation of ARG-007 into global markets, addressing a major gap in stroke treatment.
TTRA Project: Drugs
State: WA
Project Partners:
Project Lead: Dr Liz Dallimore
TTRA Funding: $1,000,000.00
Co-Contribution: $1,419,704.00 cash
Project term: 1 July 2025 – 31 July 2026
